Details

Autor(en) / Beteiligte

• da Silva, Andressa Letícia Lopes
• de Araújo, Thiago Pina Goes
• de Albuquerque Ferreira, Shakira Cavalcante
• Leite, Anderson Brandão
• da Silva, João Kaycke Sarmento
• Albuquerque, Lilyana Waleska Nunes
• de Lima, Ana Rachel Vasconcelos
• Barros, Herbert Charles Silva
• Silva, Leandro Rocha
• da Silva-Júnior, Edeildo Ferreira
• de Araújo-Júnior, João Xavier
• Neto, Vivaldo Moura
• de Queiroz, Aline Cavalcanti
• Alexandre-Moreira, Magna Suzana

Titel

PI3K Signaling Pathways as a Molecular Target for Glioblastoma Multiforme

Ist Teil von

• Current protein & peptide science, 2024, Vol.25 (1), p.12

Ort / Verlag

United Arab Emirates

Erscheinungsjahr

2024

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Glioblastoma multiforme (GBM) is the most common type of cancer that affects the central nervous system (CNS). It currently accounts for about 2% of diagnosed malignant tumors worldwide, with 296,000 new cases reported per year. The first-choice treatment consists of surgical resection, radiotherapy, and adjuvant chemotherapy, which increases patients' survival by 15 months. New clinical and pre-clinical research aims to improve this prognosis by proposing the search for new drugs that effectively eliminate cancer cells, circumventing problems such as resistance to treatment. One of the promising therapeutic strategies in the treatment of GBM is the inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway, which is closely related to the process of tumor carcinogenesis. This review sought to address the main scientific studies of synthetic or natural drug prototypes that target specific therapy co-directed via the PI3K pathway, against human glioblastoma.